Pharmacokinetics Study of Famitinib Malate Capsules in Healthy Subjects
This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.
Solid Tumor
DRUG: Famitinib Malate Capsules|DRUG: Famitinib Malate Capsules|DRUG: Famitinib Malate Capsules|DRUG: Famitinib Malate Capsules|DRUG: Famitinib Malate Capsules
Maximum observed plasma concentration (Cmax) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Area under the plasma concentration versus time curve (AUC0-t) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Area under the plasma concentration versus time curve (AUC0-∞) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Time to maximum observed plasma concentration (Tmax) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Elimination half-life (T1/2) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Apparent oral clearance (CL/F) for Famitinib after Single dose, from Day 1 to Day 9 after the first dose|Apparent Volume of Distribution (Vz/F) Famitinib after Single dose, from Day1 to Day9 after the first dose|Maximum observed plasma concentration (Cmax) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Area under the plasma concentration versus time curve (AUC0-t) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Area under the plasma concentration versus time curve (AUC0-∞) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Time to maximum observed plasma concentration (Tmax) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Time to elimination half-life (T1/2) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Apparent oral clearance (CL/F) for SHR116637 after Single dose, from Day 1 to Day 9 after the first dose|Apparent Volume of Distribution (Vz/F) SHR116637 after Single dose, from Day 1 to Day 9 after the first dose
Number of subjects with adverse events and severity of adverse events, from Day 1 to Day 16 after the first dose
This is a single-center, randomized, open-label study to compare the pharmacokinetic profiles of Famitinib and its metabolite SHR116637 at different doses/specifications.